CA Patent

CA2498111A1 — Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors

Assigned to Merck and Co Inc · Expires 2004-03-25 · 22y expired

What this patent protects

8,9-Dihydroxydihydropyridopyrazine-1,6-diones and 8,9-dihydroxypyridopyrazin e- 1,6-diones are inhibitors of HIV integrase and inhibitors of HIV replication . In one embodiment, the pyridopyrazinediones are of Formula (I): (I),wherein R1, R2, R3, R4 and R5 are defined herein. The…

USPTO Abstract

8,9-Dihydroxydihydropyridopyrazine-1,6-diones and 8,9-dihydroxypyridopyrazin e- 1,6-diones are inhibitors of HIV integrase and inhibitors of HIV replication . In one embodiment, the pyridopyrazinediones are of Formula (I): (I),wherein R1, R2, R3, R4 and R5 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredien ts in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing , treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are described.

Drugs covered by this patent

Patent Metadata

Patent number
CA2498111A1
Jurisdiction
CA
Classification
Expires
2004-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.